Share-based compensation
expenses 7,013 3,827
-------------------- -------------------
Adjusted operating loss (24,063) (34,485)
-------------------- -------------------
Net loss (29,822) (38,907)
Share-based compensation
expenses 7,013 3,827
Income tax (benefits)/expenses (5,205) 119
Interest income (2,264) (2,901)
Interest expense 5,314 4,105
Adjusted EBIT (24,964) (33,757)
-------------------- -------------------
Net loss attributable to Zepp
Health Corporation (29,741) (38,857)
Share-based compensation
expenses 7,013 3,827
-------------------- -------------------
Adjusted net loss attributable
to Zepp Health Corporation([)
(2]) (22,728) (35,030)
==================== ===================
Adjusted net loss per share
attributable to Zepp Health
Corporation
Adjusted basic loss per
ordinary share (0.09) (0.14)
Adjusted diluted loss per
ordinary share (0.09) (0.14)
Adjusted net loss per ADS (16
ordinary shares equal to
1 ADS)([3])
ADS -- basic (1.49) (2.16)
ADS -- diluted (1.49) (2.16)
Weighted average number of
shares used in computing
adjusted net loss per share
Ordinary share -- basic 243,679,883 259,433,512
Ordinary share -- diluted 243,679,883 259,433,512
Share-based compensation
expenses included are
follows:
Selling and marketing 497 368
General and administrative 3,154 1,812
Research and development 3,362 1,647
-------------------- -------------------
Total 7,013 3,827
-------------------- -------------------
View original content:https://www.prnewswire.com/news-releases/zepp-health-corporation-reports-third-quarter-2024-unaudited-financial-results-302308549.html
SOURCE Zepp Health Corp.
(END) Dow Jones Newswires
November 18, 2024 20:00 ET (01:00 GMT)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。